Lung (includes NSCLC, SCLC, Mesothelioma)

Scientists Identify 170 Potential Lung Cancer Drug Targets Using Unique Cellular Library

(UT Southwestern) Apr 19, 2018 - After testing more than 200,000 chemical compounds, UT Southwestern’s Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

read press release

Op-Ed: The Problem With Miracle Cancer Cures

(New York Times) Apr 19, 2018 - The promise of new treatments like immunotherapies have blurred the line between cure and comfort — and between hope and hopelessness — disrupting the fragile equilibrium that we doctors have long taken for granted.

read article

Germany's Merck Seeks Partners For Cancer And Immune System Drugs

(Reuters) Apr 20, 2018 - Merck KGaA will seek development partners for experimental treatments including tepotinib as the German company looks to licensing deals to help fund clinical trials, according to its head of drug R&D.

read article

Handgrip Strength Predicts Survival in Early Lung Cancer

(Medscape Medical News) Apr 23, 2018 - Measuring handgrip strength is a cheap, easy, and objective indicator of short- and longer-term survival in patients with inoperable stage I lung cancer.

read article (free registration required)

US FDA Approves Tagrisso As 1st-Line Treatment For EGFR-mutated Non-small Cell Lung Cancer

(AstraZeneca) Apr 18, 2018 - AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations, (exon 19 deletions or exon 21 L858R mutations), as detected by an FDA-approved test.

read corporate press release

AstraZeneca Wins U.S. Approval For 1st-Line Use Of Lung Cancer Drug

(Reuters) Apr 18, 2018 - U.S. regulators have expanded use of AstraZeneca’s lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic mutation, the company said on Wednesday.

read article

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review

(BMS) Apr 18, 2018 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application for Opdivo (nivolumab) to treat patients with small cell lung cancer (SCLC) whose disease has progressed after two or more prior lines of therapy. The FDA action date is August 16, 2018.

read corporate press release

Roche Expands Indication for cobas® EGFR Mutation Test v2 as a Companion Diagnostic with TAGRISSO®

(The Business Journals) Apr 18, 2018 - New indication as a companion diagnostic with AstraZeneca's TAGRISSO® (osimertinib) in first line treatment of patients with non-small cell lung cancer (NSCLC); results for EGFR mutations can be available in less than one day with the cobas® EGFR Mutation Test v2 to determine if patients can benefit from TAGRISSO®.

read article

Implant Will Show When Cancer Is Present By Generating Artificial Mole On Skin

(The Telegraph [UK]) Apr 18, 2018 - An implant which detects cancer in the body and causes a small artificial mole to appear on the skin as an early warning sign has been developed by scientists.

read article

First Opinion: Combination Immunotherapy May Have Failed In The Incyte/Merck Trial, But It’s Here To Stay

(STAT) Apr 23, 2018 - The failure of Incyte’s Phase 3 clinical trial of epacadostat combined with Keytruda, Merck’s breakthrough checkpoint inhibitor, for people newly diagnosed with melanoma was a big disappointment to the companies, the pharmaceutical industry, and patients.

read article

Elderly Non-Small Cell Lung Cancer Patients Are Less Likely To Benefit From Treatment With Simultaneous Radio- And Chemotherapy

(ESTRO 37) Apr 20, 2018 - An analysis of elderly patients treated in a phase II trial of radiotherapy combined with chemotherapy in non-small cell lung cancer (NSCLC) has shown that they were less likely to benefit than younger patients if the two treatments were given at the same time.

read press release

Boston Biomedical Inc. Initiates Two Studies Evaluating WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S*)

(Morningstar) Apr 25, 2018 - Boston Biomedical, Inc., an industry leader in the development of next-generation cancer therapeutics, today announced that it has initiated dosing of the first patient in each of two clinical studies evaluating DSP-7888, an investigational cancer peptide vaccine.

read article

Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer

(Corvus) Apr 26, 2018 - Three-arm trial will evaluate CPI-006 as monotherapy, in combination with CPI-444 adenosine antagonist and in combination with pembrolizumab.

read corporate press release

American Association For Cancer Research To Host First AACR Bladder Cancer Conference In Denver, 2019

(UCCC/Colorado Cancer Blogs) Apr 25, 2018 - In May 2019, for the first time, AACR will hold a conference focused on advances in bladder cancer, titled Bladder Cancer: Transforming the Field.

read article

AstraZeneca Reports Results From the ARCTIC Trial In Third-Line Non-Small Cell Lung Cancer

(AstraZeneca) Apr 24, 2018 - AstraZeneca and MedImmune, its global biologics research and development arm, today announced high-level results from the Phase III ARCTIC trial in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least two prior treatments.

read corporate press release

AstraZeneca Flop A Fresh Blow To Cancer Immunotherapy Combination

(Reuters) Apr 24, 2018 - The concept of combining two immunotherapy drugs to fight lung cancer - not so long ago one of the hottest ideas in cancer research - has suffered a fresh blow from the failure of an AstraZeneca clinical study.

read article

Checkmate Pharmaceuticals Announces Start of Phase 1b Trial of CMP‐001 in Combination with Anti‐PD‐L1 Immunotherapy in Anti‐PD‐1/PD‐L1 Resistant Advanced Non‐Small Cell Lung Cancer

(Morningstar) Apr 24, 2018 - Checkmate Pharmaceuticals announced that it had initiated treatment with CMP001 combined with atezolizumab (TECENTRIQ®) in a Phase 1b clinical trial of patients with advanced non‐small cell lung cancer (NSCLC) and disease progression on prior anti‐PD‐1/PD‐L1 therapy.

read article

EU Reviewing MSD’s Keytruda/Chemo Combo

(PharmaTimes [UK]) Apr 24, 2018 - European regulators have kicked off a review of MSD’s Keytruda/pemetrexed combination for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC).

read article

Size, Structure Help Poziotinib Pose Threat To Deadly Exon 20 Lung Cancer

(MD Anderson) Apr 23, 2018 - A drug that failed to effectively strike larger targets in lung cancer hits a bulls-eye on the smaller target presented by a previously untreatable form of the disease, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine.

read press release

New, High-Impact Studies to Be Featured at World’s Largest Clinical Cancer Research Meeting

(ASCO) Apr 25, 2018 - The latest in clinical cancer research, from new treatment options and advances in precision medicine to insights for improving access to care, will be highlighted in the official Press Program for the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO).

read press release
Next Page